Blood pressure benefits start early

Blood pressure-lowering treatment reduced cardiovascular events quickly, but relative benefits did not grow with longer treatment.
*Individual participant data meta-analysis of randomized trials; Level 1.

Citation

Yang Q, Bidel Z, Canoy D, et al. A meta-analysis of the long-term effects of antihypertensive therapy on the risk of major cardiovascular disease across 51 randomized trials. Nature Medicine. 2026. doi:10.1038/s41591-026-04514-3

Background

Blood pressure medicines are known to prevent heart attacks, strokes, heart failure, and cardiovascular death. This study tested whether benefits become proportionally larger the longer treatment continues.

Patients

357,314 adults from 51 randomized trials. People with heart failure at study start and those missing key follow-up data were excluded.

Intervention

Blood pressure-lowering treatment, analyzed as a 5 mmHg lower systolic blood pressure.

Control

Placebo, less intensive treatment, or a treatment strategy with smaller blood pressure reduction.

Outcome

Major cardiovascular events: fatal or nonfatal stroke, ischemic heart disease, or heart failure. Death outcomes were also assessed.

Follow-up Period

Median 4.2 years.

Results

Outcome Key result
Major cardiovascular events, year 1 (primary) 12% lower risk; hazard ratio 0.88 (95% confidence interval 0.84–0.91)
Major cardiovascular events, 5 years (primary) Absolute reduction 1.25%; number needed to treat 80
Stroke, 5 years Absolute reduction 0.52%; number needed to treat 192
Heart failure, year 1 27% lower risk; hazard ratio 0.73 (95% confidence interval 0.65–0.80)
Death from any cause, overall 4% lower risk; hazard ratio 0.96 (95% confidence interval 0.94–0.99)

Major cardiovascular event reductions were significant early, but years 4–5 and beyond 5 years were not significant. Analyses followed intention-to-treat principles. Absolute benefit accumulated over time, but proportional benefit did not compound.

Limitations

Median follow-up may be too short to detect very long-term effects. Later follow-up included only survivors without earlier events, which can bias time-specific comparisons. Participants were mostly older adults, so results should not be extended to young, low-risk adults.

Funding

British Heart Foundation; no reported funder role.

Clinical Application

Treat based on cardiovascular risk; do not medicate low-risk patients solely expecting larger benefits from earlier, longer therapy.